Lyell Immunopharma, Inc. (LYEL) — Total Liabilities
| Fiscal Year | Total Liabilities | Change YoY |
|---|---|---|
| 2025 | $91.85M | -15.0% |
| 2024 | $108.03M | +13.6% |
| 2023 | $95.08M | -8.9% |
| 2022 | $104.31M | -47.2% |
| 2021 | $197.62M | +4.1% |
| 2020 | $189.84M | — |
| Fiscal Year | Total Liabilities | Change YoY |
|---|---|---|
| 2025 | $91.85M | -15.0% |
| 2024 | $108.03M | +13.6% |
| 2023 | $95.08M | -8.9% |
| 2022 | $104.31M | -47.2% |
| 2021 | $197.62M | +4.1% |
| 2020 | $189.84M | — |